Central nervous system toxicities of chemotherapeutic agents

References

• Paudyal B, Viets R, Skliut M. A case of low-dose oral methotrexate-induced reversible neurotoxicity. Am J Neuroradiol 2010;31(9):E77
   Google Scholar
• Verstappen CCP, Heimans JJ, Hoekman K, Postma TJ. Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 2003;63(15):1549-63
   PubMed Web of Science ®Google Scholar
• Monje M, Wen PY. Neurological complications of oncological therapy. In: Jolesz F, editors, Handbook of neuro-oncology neuroimaging. Academic Press; Newton HB, USA; 2007. p. 102-18
   Google Scholar
• Hammack JE. Neurologic complications of chemotherapy and biologic therapies. In: Schiff D, O’Neill BP, editors. Principles and practice of neuro-oncology. 1st edition. McGraw-Hill Professional, New York, NY, USA; 2005. p. 679-710. Chapter 31
   Google Scholar
• Moore BE, Somers NP, Smith TW. Methotrexate-related nonnecrotizing multifocal axonopathy detected by beta-amyloid precursor protein immunohistochemistry. Arch Pathol Lab Med 2002;126(1):79-81
   PubMed Web of Science ®Google Scholar
• Blay JY, Conroy T, Chevreau C, et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 1998;16(3):864-71
   PubMed Web of Science ®Google Scholar
• Widemann BC, Sung E, Anderson L, et al. Pharmacokinetics and Metabolism of the Methotrexate Metabolite 2,4-Diamino-N 10-methylpteroic Acid. J Pharmacol Exp Ther 2000;294(3):894-901
   PubMed Web of Science ®Google Scholar
• Zoubek A, Zaunschirm HA, Lion T, et al. Successful carboxypeptidase G2 rescue in delayed methotrexate elimination due to renal failure. Pediatr Hematol Oncol 1995;12(5):471-7
   PubMed Web of Science ®Google Scholar
• Green JM. Glucarpidase to combat toxic levels of methotrexate in patients. Ther Clin Risk Manag 2012;8:403-13
   PubMed Web of Science ®Google Scholar
• Widemann BC, Balis FM, Shalabi A, et al. Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2. J Natl Cancer Inst 2004;96(20):1557-9
   PubMedGoogle Scholar
• Bradley AM, Buie LW, Kuykendal A, Voorhees PM. Successful use of intrathecal carboxypeptidase G2 for intrathecal methotrexate overdose: a case study and review of the literature. Clin Lymphoma Myeloma Leuk 2012;13(2):166-70
   PubMed Web of Science ®Google Scholar
• Jardine LF, Ingram LC, Bleyer WA. Intrathecal leucovorin after intrathecal methotrexate overdose. J Pediatr Hematol Oncol 1996;18(3):302-4
   PubMed Web of Science ®Google Scholar
• Baker WJ, Royer GL, Weiss RB. Cytarabine and neurologic toxicity. J Clin Oncol 1991;9(4):679-93
   PubMed Web of Science ®Google Scholar
• Rubin EH, Andersen JW, Berg DT, et al. Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia. J Clin Oncol 1992;10(6):948-53
   PubMed Web of Science ®Google Scholar
• Saito B, Nakamaki T, Nakashima H, et al. Reversible posterior leukoencephalopathy syndrome after repeat intermediate-dose cytarabine chemotherapy in a patient with acute myeloid leukemia. Am J Hematol 2007;82(4):304-6
   PubMed Web of Science ®Google Scholar
• Han CH, Findlay MP. Chemotherapy-induced reversible posterior leucoencephalopathy syndrome. Intern Med J 2010;40(2):153-9
   PubMed Web of Science ®Google Scholar
• Lorigan P, Verweij J, Papai Z, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 2007;25(21):3144-50
   PubMed Web of Science ®Google Scholar
• David KA, Picus J. Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Clin Oncol 2005;28(3):277-80
   PubMed Web of Science ®Google Scholar
• Gonzalez-Angulo AM, Orzano JA, Davila E. Ifosfamide-induced encephalopathy. South Med J 2002;95(10):1215-17
   PubMed Web of Science ®Google Scholar
• Pelgrims J, De Vos F, Van den Brande J, et al. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer 2000;82(2):291-4
   PubMed Web of Science ®Google Scholar
• Küpfer A, Aeschlimann C, Wermuth B, Cerny T. Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet 1994;343(8900):763-4
   PubMed Web of Science ®Google Scholar
• Imtiaz S, Muzaffar N. Ifosfamide neurotoxicty in a young female with a remarkable response to thiamine. J Pak Med Assoc 2010;60(10):867-9
   PubMed Web of Science ®Google Scholar
• Hamadani M, Awan F. Role of thiamine in managing ifosfamide-induced encephalopathy. J Oncol Pharm Pract 2006;12(4):237-9
   PubMedGoogle Scholar
• Richards A, Marshall H, McQuary A. Evaluation of methylene blue, thiamine, and/or albumin in the prevention of ifosfamide-related neurotoxicity. J Oncol Pharm Pract 2011;17(4):372-80
   PubMedGoogle Scholar
• Riehl JL, Brown WJ. Acute cerebellar syndrome secondary to 5-fluorouracil therapy. Neurology 1964;14:961-7
   PubMed Web of Science ®Google Scholar
• Akitake R, Miyamoto S, Nakamura F, et al. Early detection of 5-FU-induced acute leukoencephalopathy on diffusion-weighted MRI. Jpn J Clin Oncol 2011;41(1):121-4
   PubMed Web of Science ®Google Scholar
• Sheikh MH, Dasgupta S, Adilieje C, et al. Capecitabine and sixth cranial nerve palsy. J Can Res Ther 2010;6(1):80-1
   PubMed Web of Science ®Google Scholar
• Videnovic A, Semenov I, Chua-Adajar R, et al. Capecitabine-induced multifocal leukoencephalopathy: a report of five cases. Neurology 2005;65(11):1792-4
   PubMed Web of Science ®Google Scholar
• Cordier P-Y, Nau A, Ciccolini J, et al. 5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases. Cancer Chemother Pharmacol 2011;68(3):823-6
   PubMed Web of Science ®Google Scholar
• Hosoi M, Yamamoto G, Imai Y, Kurokawa M. Reversible posterior leukoencephalopathy syndrome following R-CHOP therapy for diffuse large B-cell lymphoma. Ann Hematol 2010;89(2):207-8
   PubMed Web of Science ®Google Scholar
• Hemmaway C, Mian A, Nagy Z. Images in haematology. Irreversible blindness secondary to posterior reversible encephalopathy syndrome following CHOP combination chemotherapy. Br J Haematol 2010;150(2):129
   PubMedGoogle Scholar
• Hennipman B, De Vries E, Bökkerink JPM, et al. Intrathecal vincristine: 3 fatal cases and a review of the literature. J Pediatr Hematol Oncol 2009;31(11):816-19
   PubMed Web of Science ®Google Scholar
• Jain S, Kapoor G. Severe life threatening neurotoxicity in a child with acute lymphoblastic leukemia receiving posaconazole and vincristine. Pediatr Blood Cancer 2010;54(5):783
   PubMed Web of Science ®Google Scholar
• Pana ZD, Roilides E. Risk of azole-enhanced vincristine neurotoxicity in pediatric patients with hematological malignancies: old problem - new dilemma. Pediatr Blood Cancer 2011;57(1):30-5
   PubMed Web of Science ®Google Scholar
• Albers JW, Chaudhry V, Cavaletti G, Donehower RC. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 2011(2):CD005228
   Google Scholar
• Saumoy M, Castells G, Escoda L, et al. Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia after treatment with fludarabine. Leuk Lymphoma 2002;43(2):433-6
   PubMed Web of Science ®Google Scholar
• Lee MS, McKinney AM, Brace JR, Santacruz K. Clinical and imaging features of fludarabine neurotoxicity. J Neuroophthalmol 2010;30(1):37-41
   PubMed Web of Science ®Google Scholar
• Chun HG, Leyland-Jones BR, Caryk SM, Hoth DF. Central nervous system toxicity of fludarabine phosphate. Cancer Treat Rep 1986;70(10):1225-8
   PubMedGoogle Scholar
• Martín G, Bellido L, Cruz JJ. Reversible Posterior Leukoencephalopathy Syndrome Induced by Sunitinib. J Clin Oncol 2007;25(23):3559
   PubMed Web of Science ®Google Scholar
• Chen A, Agarwal N. Reversible posterior leucoencephalopathy syndrome associated with sunitinib. Intern Med J 2009;39(5):341-2
   PubMed Web of Science ®Google Scholar
• Govindarajan R, Adusumilli J, Baxter DL, et al. Reversible Posterior Leukoencephalopathy Syndrome Induced by RAF Kinase Inhibitor BAY 43-9006. J Clin Oncol 2006;24(28):e48
   Google Scholar
• Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006;354(9):980-2
   PubMedGoogle Scholar
• Artunay O, Yuzbasioglu E, Rasier R, et al. Posterior reversible encephalopathy syndrome after intravitreal bevacizumab injection in patient with choroidal neovascular membrane secondary to age-related maculopathy. J Ocul Pharmacol Ther 2010;26(3):301-3
   PubMed Web of Science ®Google Scholar
• Mavragani CP, Vlachoyiannopoulos PG, Kosmas N, et al. A case of reversible posterior leucoencephalopathy syndrome after rituximab infusion. Rheumatology 2004;43(11):1450-1
   PubMed Web of Science ®Google Scholar